Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis

Abstract

Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-centre studies have certainly contributed to our understanding of disease pathogenesis, but to adequately address the major areas of unmet need, multi-partner, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient-representative organizations. In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing and treating PsA allowing for better short-term and long-term outcomes.

Higher Synovial Immunohistochemistry Reactivity of IL-17A, Dkk1, and TGF-β1 in Patients with Early Psoriatic Arthritis and Rheumatoid Arthritis Could Predict the Use of Biologics

“…Having a diagnostic tool to predict the evolution of these patients could be very useful [28]. To date, many studies have evaluated the ability of different parameters to predict poor prognosis [29][30][31]. Surrogate markers of disease severity, such as the need for biological agents or estimation of treatment intensity, could provide useful results [32].…”

Molecular profiling of clinical remission in psoriatic arthritis reveals dysregulation of FOS and CCDC50 genes: a gene expression study

“…Several genetic, circulating, and tissue factors have been studied as biomarkers in the management of different aspects of PsA, including diagnosis and assessment or prediction of disease activity, severity, and response to treatment ( 9 – 13 ). However, none of these has been extensively validated and then translated into routine clinical practice ( 10 , 14 ). In particular, despite remission being recommended as the primary goal in PsA treatment, to our knowledge, no studies have been specifically designed to identify the underlying molecular mechanisms and potential biomarkers.…”